Immix Biopharma (NASDAQ:IMMX) Announces Earnings Results, Beats Estimates By $0.06 EPS

Immix Biopharma (NASDAQ:IMMX) posted its quarterly earnings data on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06, Zacks reports.

Immix Biopharma Stock Up 0.5 %

IMMX stock opened at $1.86 on Wednesday. The company’s 50-day moving average price is $2.10 and its two-hundred day moving average price is $2.53. Immix Biopharma has a 12 month low of $1.55 and a 12 month high of $7.75. The firm has a market cap of $49.13 million, a P/E ratio of -2.00 and a beta of 0.17.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Immix Biopharma in a report on Friday, July 26th.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.